ClinicalTrials.gg
CompletedNCT01077544Updated Dec 29, 2020Results posted

A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)

A Phase 1 interventional study of Nilotinib in Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia, sponsored by Novartis Pharmaceuticals. Completed at 12 sites in 4 countries. Open to participants aged 1 Year to 17 Years. Per ClinicalTrials.gov, last updated 2020-12-29.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
15
Allocation
Non-randomized
Ages
1 Year to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive — 2 open to participants now, 3 under way, none of them phase 3. nilotinib · Leukemia, Myelogenous, Chronic, BCR-ABL Positive.

Enrollment
53rd of 66
15 · median 55
Started
2011
with 3 others
Phase 1
6 of 66
none open now
Registered
19th of 66
by date
Lead sponsor
35 of 66
Novartis Pharmaceuticals

Among the 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, this one is the 53rd largest by enrollment, is one of 4 that started in 2011, is one of 6 in phase 1, and was the 19th registered.

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

894 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 109 are open to participants now.

Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →

Open to participants now

2 of the 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About nilotinib

nilotinib: first FDA approval 2007 (TASIGNA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 79 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 48 (61%) set no upper age limit and 20 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.

This study: 1 Year to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, or all of them as a file.
02

Study summary

This study will assess the pharmacokinetics of nilotinib in Ph+ CML pediatric patients that are newly diagnosed or resistant or intolerant to imatinib or dasatinib or refractory or relapsed Ph+ ALL compared to the adult populations. It will also evaluate safety and activity of nilotinib as secondary objectives.

03

Conditions studied

  • Chronic Myeloid Leukemia
  • Acute Lymphoblastic Leukemia

Keywords

  • Chronic Myeloid Leukemia
  • Acute Lymphoblastic Leukemia
  • Ph+ CML
  • Ph+ ALL
  • pediatric
  • nilotinib
  • imatinib
  • chronic phase
  • accelerated phase
  • newly diagnosed Ph+ CML
  • dasatinib
04

Who can participate

Ages eligible
1 Year to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must have one of the following: newly diagnosed CP Ph+CML, CP or AP resistant/ intolerant to imatinib and/or dasatinib, or Ph+ ALL either after or refractory to standard therapy
  • adequate renal, hepatic and pancreatic function

Exclusion criteria

Exclusion Criteria:

  • patients receiving therapy with strong inhibitors and/or inducers and treatments cannot be stopped or changed to a different medication at least 14 days prior to starting study drug
  • patients receiving therapy with any medications with a known risk or possible risk to prolong the and the treatment cannot be either discontinued or switched to a different medication prior to starting study drug.
  • gastrointestinal impairment or disease that may interfere with drug absorption
  • liver, pancreatic or severe renal disease unrelated to disease under study
  • impaired cardiac function
  • patients who received dasatinib within 3 days of starting study drug
  • patients who received imatinib within 5 days of starting study drug
  • patients receiving hydroxyurea or that has not been discontinued at least 1 week after initiation of nilotinib
  • patients who received hematopoietic growth factors within 7 days of starting study drug or Pegfilgrastim (Neulasta®) within 14 days of starting study drug
  • patients with Stem Cell Transplant (SCT) or Rescue without TBI: Evidence of active graft vs. host disease and \< 3 months since SCT

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Group 1

    1 year to \< 10 years pediatric patients with newly diagnosed CP-Ph+ CML, or CP or AP-Ph+ CML resistant/intolerant to imatinib and/or dasatinib, or relapsed/refractory Ph+ ALL (acute lymphoblastic leukemia) treated at the proposed dose of 230 mg/m2 bid.

    Drug: Nilotinib

  • Experimental
    Group 2

    \>= 10 years to \<18 years pediatric patients with newly diagnosed CP-Ph+ CML, or CP or AP-Ph+ CML resistant/intolerant to imatinib and/or dasatinib, or relapsed/refractory Ph+ ALL (acute lymphoblastic leukemia) treated at the proposed dose of 230 mg/m2 bid.

    Drug: Nilotinib

Interventions

  • Nilotinib capsules were delivered in bottles with dose strengths of 50mg, 150mg and 200mg. Patients were administered nilotinib 230 mg/m2 (per BSA) bid, orally, rounded to the nearest 50 mg (max single dose 400 mg) for 28 days (1 cycle) for up to 12 cycles prior to protocol amendment 3 and up to 24 cycles post amendment 3. Capsules were to be swallowed whole with water. Apple sauce (puréed apple) may have been used as a vehicle for dosing where capsules were not able to be swallowed whole with water.

    Also known as: AMN107

06

What researchers measure

Primary outcomes

  1. Summary of Nilotinib Non-compartmental PK Parameters: Cmax

    The full PK profiles of nilotinib in pediatric patients were assessed using serial sampling following a single 230 mg/m2 dose on Cycle 1 Day 1.

    Time frame: Cycle 1 Day 1

  2. Summary of Nilotinib Non-compartmental PK Parameters: Tmax

    The full PK profiles of nilotinib in pediatric patients were assessed using serial sampling following a single 230 mg/m2 dose on Cycle 1 Day 1.

    Time frame: Cycle 1 Day 1

  3. Summary of Nilotinib Non-compartmental PK Parameters: AUClast (Last = 24h)

    The full PK profiles of nilotinib in pediatric patients were assessed using serial sampling following a single 230 mg/m2 dose on Cycle 1 Day 1.

    Time frame: Cycle 1 Day 1

  4. Summary of Nilotinib Non-compartmental PK Parameters: AUC0-12h

    The full PK profiles of nilotinib in pediatric patients were assessed using serial sampling following a single 230 mg/m2 dose on Cycle 1 Day 1.

    Time frame: Cycle 1 Day 1

  5. Summary of Nilotinib Steady-state PK Parameters: AUCss

    The steady-state PK profiles of nilotinib in pediatric patients were estimated using trough sampling following multiple 230 mg/m2 bid doses

    Time frame: Cycle 1 Day 8 - Cycle 1 Day 28

  6. Summary of Nilotinib Steady-state PK Parameters: CLF (Body Surface Area (BSA) Adjusted)

    The steady-state PK profiles of nilotinib in pediatric patients were estimated using trough sampling following multiple 230 mg/m2 bid doses

    Time frame: Cycle 1 Day 8 - Cycle 1 day 28

  7. Summary of Nilotinib Steady-state PK Parameters: Cmin

    The full PK profiles of nilotinib in pediatric patients were assessed using serial sampling following a single 230 mg/m2 dose.

    Time frame: Cycle 1 Day 8 - Cycle 1 Day 28

Secondary outcomes

  1. Number of Ph+ CML Participants With Confirmed Complete Hematologic Response (CHR)

    A confirmed complete hematological response (CHR) is defined when all of the following criteria are achieved at two consecutive assessments, at least 4 weeks apart: white blood cell (WBC) count \< 10 × 109/L; platelet \< 450 × 109/L; basophils \< 5%; no blasts and promyelocytes in peripheral blood (PB); myelocytes + metamyelocytes \< 5% in PB; and no extramedullary involvement. The information used for hematological assessment was to be obtained from the laboratory and extramedullary data, all merged by patient and date.

    Time frame: minimum of 12 cycles (28 days per cycle)

  2. Number of Ph+ CML Participants With Cytogenic Response

    Cytogenetic response was initially assessed as the percentage of Ph+ metaphases in the bone marrow (BM) and performed within 21 days prior to study entry. A major cytogenetic response (0% to 35% Ph+ metaphases test positive for the Philadelphia chromosome) combines both complete cytogenetic (CCyR) and partial cytogenetic response (PCyR). CCyR implies 0% Ph+ metaphases in the BM, PCyR is \> 0% to 35%, minor cytogenetic response (mCyR) is \> 35% to 65%, minimal response is \> 65% to 95% and no response is \> 95% Ph+ metaphases in the BM.

    Time frame: minimum of 12 cycles (28 days per cycle)

  3. Number of Ph+ CML Participants With Major Molecular Response (MMR)

    The bcr-abl gene fusion encodes for a BCR-ABL fusion protein. Depending on the precise location of the fusion, the molecular weight of this protein can range from 185 to 210 kDa. Consequently BCR-ABL is referred to as p185 or p210 transcript. For the patients expressing the major BCR-ABL transcript p210, molecular response was defined and reported as the percent ratio of BCR-ABL transcripts/control gene transcripts converted to a reference standard according to the International Scale (IS). A major molecular response (MMR) is defined as a BCR-ABL/control gene ratio ≤ 0.1% (equal to a 3 log reduction in BCR-ABL transcripts) on the IS. In this study, the control gene was abl.

    Time frame: minimum of 12 cycles (28 days per cycle)

  4. Efficacy Endpoints for Ph+ ALL Patients

    Best Response in Ph+ ALL patients was defined as either Complete Remission (CR) with platelet recovery, Complete Remission (CR) with incomplete platelet recovery, Partial Remission (PR) or Stable disease. Stable disease was defined is defined as failure to qualify for either CR, PR, or progressive disease.

    Time frame: minimum of 12 cycles (28 days per cycle)

07

Results

Posted Jan 27, 2016

Participant flow

Participant flow — Overall Study
MilestoneGroup 1Group 2
Started87
Completed52
Not completed35
Withdrew: New cancer therapy33
Withdrew: Adverse event01
Withdrew: Disease progression01

Outcome measures

PrimarySummary of Nilotinib Non-compartmental PK Parameters: Cmax

The full PK profiles of nilotinib in pediatric patients were assessed using serial sampling following a single 230 mg/m2 dose on Cycle 1 Day 1.

Time frame:
Cycle 1 Day 1
Reported as:
Geometric mean · ng/mL
Summary of Nilotinib Non-compartmental PK Parameters: Cmax
ng/mLGroup 1Group 2
Summary of Nilotinib Non-compartmental PK Parameters: Cmax405.111 ± 42.5402.715 ± 35.2
SecondaryNumber of Ph+ CML Participants With Confirmed Complete Hematologic Response (CHR)

A confirmed complete hematological response (CHR) is defined when all of the following criteria are achieved at two consecutive assessments, at least 4 weeks apart: white blood cell (WBC) count \< 10 × 109/L; platelet \< 450 × 109/L; basophils \< 5%; no blasts and promyelocytes in peripheral blood (PB); myelocytes + metamyelocytes \< 5% in PB; and no extramedullary involvement. The information used for hematological assessment was to be obtained from the laboratory and extramedullary data, all merged by patient and date.

Time frame:
minimum of 12 cycles (28 days per cycle)
Reported as:
Number · Participants
Number of Ph+ CML Participants With Confirmed Complete Hematologic Response (CHR)
ParticipantsGroup 1Group 2
Yes55
No01
PrimarySummary of Nilotinib Non-compartmental PK Parameters: Tmax

The full PK profiles of nilotinib in pediatric patients were assessed using serial sampling following a single 230 mg/m2 dose on Cycle 1 Day 1.

Time frame:
Cycle 1 Day 1
Reported as:
Median · h
Summary of Nilotinib Non-compartmental PK Parameters: Tmax
hGroup 1Group 2
Summary of Nilotinib Non-compartmental PK Parameters: Tmax2.000 ± 163.10503.000 ± 140.8314
PrimarySummary of Nilotinib Non-compartmental PK Parameters: AUClast (Last = 24h)

The full PK profiles of nilotinib in pediatric patients were assessed using serial sampling following a single 230 mg/m2 dose on Cycle 1 Day 1.

Time frame:
Cycle 1 Day 1
Reported as:
Geometric mean · ng*h/mL
Summary of Nilotinib Non-compartmental PK Parameters: AUClast (Last = 24h)
ng*h/mLGroup 1Group 2
Summary of Nilotinib Non-compartmental PK Parameters: AUClast (Last = 24h)4160.969 ± 38.55707.368 ± 51.2
PrimarySummary of Nilotinib Non-compartmental PK Parameters: AUC0-12h

The full PK profiles of nilotinib in pediatric patients were assessed using serial sampling following a single 230 mg/m2 dose on Cycle 1 Day 1.

Time frame:
Cycle 1 Day 1
Reported as:
Geometric mean · ng*h/mL
Summary of Nilotinib Non-compartmental PK Parameters: AUC0-12h
ng*h/mLGroup 1Group 2
Summary of Nilotinib Non-compartmental PK Parameters: AUC0-12h2795.782 ± 35.73393.296 ± 30.4
PrimarySummary of Nilotinib Steady-state PK Parameters: AUCss

The steady-state PK profiles of nilotinib in pediatric patients were estimated using trough sampling following multiple 230 mg/m2 bid doses

Time frame:
Cycle 1 Day 8 - Cycle 1 Day 28
Reported as:
Geometric mean · ng*h/mL
Summary of Nilotinib Steady-state PK Parameters: AUCss
ng*h/mLGroup 1Group 2
Summary of Nilotinib Steady-state PK Parameters: AUCss15129.182 ± 38.014383.076 ± 33.6
PrimarySummary of Nilotinib Steady-state PK Parameters: CLF (Body Surface Area (BSA) Adjusted)

The steady-state PK profiles of nilotinib in pediatric patients were estimated using trough sampling following multiple 230 mg/m2 bid doses

Time frame:
Cycle 1 Day 8 - Cycle 1 day 28
Reported as:
Geometric mean · L/h/m^2)
Summary of Nilotinib Steady-state PK Parameters: CLF (Body Surface Area (BSA) Adjusted)
L/h/m^2)Group 1Group 2
Summary of Nilotinib Steady-state PK Parameters: CLF (Body Surface Area (BSA) Adjusted)15.356 ± 38.715.922 ± 37.0
PrimarySummary of Nilotinib Steady-state PK Parameters: Cmin

The full PK profiles of nilotinib in pediatric patients were assessed using serial sampling following a single 230 mg/m2 dose.

Time frame:
Cycle 1 Day 8 - Cycle 1 Day 28
Reported as:
Geometric mean · ng/mL
Summary of Nilotinib Steady-state PK Parameters: Cmin
ng/mLGroup 1Group 2
Summary of Nilotinib Steady-state PK Parameters: Cmin804.791 ± 33.71072.850 ± 20.5
SecondaryNumber of Ph+ CML Participants With Cytogenic Response

Cytogenetic response was initially assessed as the percentage of Ph+ metaphases in the bone marrow (BM) and performed within 21 days prior to study entry. A major cytogenetic response (0% to 35% Ph+ metaphases test positive for the Philadelphia chromosome) combines both complete cytogenetic (CCyR) and partial cytogenetic response (PCyR). CCyR implies 0% Ph+ metaphases in the BM, PCyR is \> 0% to 35%, minor cytogenetic response (mCyR) is \> 35% to 65%, minimal response is \> 65% to 95% and no response is \> 95% Ph+ metaphases in the BM.

Time frame:
minimum of 12 cycles (28 days per cycle)
Reported as:
Number · Participants
Number of Ph+ CML Participants With Cytogenic Response
ParticipantsGroup 1Group 2
Complete cytogenic response (CCyR)22
Partial cytogenic response (PCyR)01
Minor cytogenic response (mCyR)01
Minimal00
None00
Absence of Ph+ at baseline31
SecondaryNumber of Ph+ CML Participants With Major Molecular Response (MMR)

The bcr-abl gene fusion encodes for a BCR-ABL fusion protein. Depending on the precise location of the fusion, the molecular weight of this protein can range from 185 to 210 kDa. Consequently BCR-ABL is referred to as p185 or p210 transcript. For the patients expressing the major BCR-ABL transcript p210, molecular response was defined and reported as the percent ratio of BCR-ABL transcripts/control gene transcripts converted to a reference standard according to the International Scale (IS). A major molecular response (MMR) is defined as a BCR-ABL/control gene ratio ≤ 0.1% (equal to a 3 log reduction in BCR-ABL transcripts) on the IS. In this study, the control gene was abl.

Time frame:
minimum of 12 cycles (28 days per cycle)
Reported as:
Number · Participants
Number of Ph+ CML Participants With Major Molecular Response (MMR)
ParticipantsGroup 1Group 2
Yes12
No44
SecondaryEfficacy Endpoints for Ph+ ALL Patients

Best Response in Ph+ ALL patients was defined as either Complete Remission (CR) with platelet recovery, Complete Remission (CR) with incomplete platelet recovery, Partial Remission (PR) or Stable disease. Stable disease was defined is defined as failure to qualify for either CR, PR, or progressive disease.

Time frame:
minimum of 12 cycles (28 days per cycle)
Reported as:
Number · Participants
Efficacy Endpoints for Ph+ ALL Patients
ParticipantsGroup 1Group 2
Complete Remission with platelet recovery21
Complete Remission w/incomplete platelet recovery00
Partial remission00
Stable disease10
Progressive disease00

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group 1—2/8 (25%)8/8 (100%)
Group 2—3/7 (42.9%)7/7 (100%)
Most frequent serious events
Most frequent serious events
EventGroup 1Group 2
NeutropeniaBlood and lymphatic system disorders0/82/7
Renal failureRenal and urinary disorders0/81/7
Appendix disorderGastrointestinal disorders1/80/7
Influenza like illnessGeneral disorders1/80/7
PyrexiaGeneral disorders1/80/7
Most frequent other events
Showing 10 of 87
Most frequent other events
EventGroup 1Group 2
NasopharyngitisInfections and infestations4/80/7
HeadacheNervous system disorders4/82/7
DiarrhoeaGastrointestinal disorders1/83/7
NauseaGastrointestinal disorders0/83/7
VomitingGastrointestinal disorders3/83/7
Blood bilirubin increasedInvestigations2/83/7
ArthralgiaMusculoskeletal and connective tissue disorders0/83/7
RhinitisInfections and infestations3/81/7
Alanine aminotransferase increasedInvestigations3/81/7
Aspartate aminotransferase increasedInvestigations3/80/7

Baseline characteristics

Full analysis set (FAS): consists of all patients who passed the screening and are enrolled into the study. Patients may or may not have taken study drug.

Age, Continuous
Age, Continuous(Years)Group 1Group 2Total
Mean6.8 ± 1.1613.7 ± 2.8110.0 ± 4.12
Sex: Female, Male
Sex: Female, Male(Participants)Group 1Group 2Total
Female347
Male538
Weight
Weight(kg)Group 1Group 2Total
Mean24.60 ± 4.73948.89 ± 17.53335.93 ± 17.328
Height
Height(cm)Group 1Group 2Total
Mean119.9 ± 7.49158.0 ± 16.32137.7 ± 23.02
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)Group 1Group 2Total
Mean16.962 ± 1.765418.944 ± 3.456317.887 ± 2.7795
08

Study locations

12 sites
  • Novartis Investigative Site
    Bordeaux, Aquitaine 33076, France
  • Novartis Investigative Site
    Lille cedex, 59037, France
  • Novartis Investigative Site
    Paris, 75571, France
  • Novartis Investigative Site
    Poitiers, 86021, France
  • Novartis Investigative Site
    Monza, MB 20900, Italy
  • Novartis Investigative Site
    Padova, PD 35128, Italy
  • Novartis Investigative Site
    Roma, RM 00161, Italy
  • Novartis Investigative Site
    Amsterdam, 1081 HV, Netherlands
  • Novartis Investigative Site
    Rotterdam, 3015 CN, Netherlands
  • Novartis Investigative Site
    West Midlands, Birmingham B4 6NH, United Kingdom
  • Novartis Investigative Site
    Sutton, Surrey SM2 5PT, United Kingdom
  • Novartis Investigative Site
    Bristol, BS2 8BJ, United Kingdom
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2011 to primary completion in Jul 2015, 50 months.

Results were first posted in Jan 2016, 6 months after primary completion.

Of 56 phase 1 interventional studies under Leukemia, Myelogenous, Chronic, BCR-ABL Positive, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 95. This study's 50 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2010
First posted
Mar 1, 2010
StartActual
Apr 14, 2011
Primary completionActual
Jul 1, 2015
CompletionActual
Jul 1, 2015
Results first posted
Jan 27, 2016
Last update
Dec 29, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 29, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01077544
Responsible party
Sponsor
First posted
Mar 1, 2010
Start date
Apr 14, 2011
Primary completion
Jul 1, 2015
Completion
Jul 1, 2015
Results posted
Jan 27, 2016
Last update
Dec 29, 2020

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nilotinib

Start the discussion